Well-known big pharma drugs cause brain damage and increase

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
152
Well-known big pharma drugs cause brain damage and increase dementia risk

Drugs, add them to the bad food as a possible cause of dementia

https://www.naturalhealth365.com/big-pharma-d...-2391.html

(NaturalHealth365) No doubt, conventional medicine is a big believer in ‘a pill for every ill’ and much of the general public gets affected by this mentality – on a daily basis. Of course, big pharma is the driving force behind this concept. Unfortunately, the increasing demand for more and more drugs is being linked to serious side effects – especially as it relates to brain health.

The reality is: evidence is mounting that these drug ‘therapies’ have side effects that can, in many cases, be worse than the original problem itself. For example, a recent study by the Indiana University School of Medicine found that anticholinergic drugs can cause cognitive impairment and a higher risk of dementia.

The researchers found reduced brain size, memory issues and lowered cognitive performance in study participants who were taking one or more anticholinergic drugs. (you think patients are being adequately informed about the risk?)

Anticholinergic drugs include over-the-counter allergy medicines, sleep aids and drugs for cardiovascular disease, COPD (chronic obstructive pulmonary disease), hypertension (high blood pressure) and other chronic diseases. And, just for the record, these anticholinergic drug brand names include: Benadryl, Dramamine, Dimetapp, Paxil, Unisom, VESIcare and Demerol.

How big pharma drugs damage your short-term memory and ability to problem-solve
Most Americans, influenced by Western medicine, are all too attracted to “drive-thru” quick-fix band-aids like these drugs – instead of lifestyle changes and more holistic solutions. Because of this, many often overlook long lists of side effects and risks that are associated with big pharma drugs. (being uninformed is also part of the problem.)

The Indiana University School of Medicine study aimed to look at the physical changes involved in accelerating cognitive decline. The study examined 451 people who were an average age of 73. Of the 451, 60 were taking at least one anticholinergic drug. The researchers used memory and cognitive tests to identify physiological changes associated with cognitive issues. They also utilized MRI scans to assess brain structure and PET scans to measure brain metabolism.

Patients that took the anticholinergic drugs were found to perform worse on cognitive tests, particularly short-term memory tests. Verbal reasoning, executive function, problem-solving and planning were also adversely affected.

Anticholinergic drugs are linked to a higher risk of dementia
The users of anticholinergic drugs also showed lower glucose metabolism levels in the hippocampus and overall brain. Glucose is a biomarker for brain activity, and the hippocampus is associated with memory and is an area that is affected in the early stages of Alzheimer’s disease.

Anticholinergic drug users also showed larger ventricles and reduced overall brain volume.

These findings clearly shine a light on what happens biologically as cognitive issues develop when anticholinergic drugs are being used. The findings are corroborated by a 2013 study out of the Indiana University Center for Aging Research – which showed that taking anticholinergics for just 60 days could cause cognitive issues.

Hopefully, these research results will serve as a warning to anyone who has ever taken anticholinergic drugs or is considering taking them. Older individuals and those with a family history of Alzheimer’s disease should think carefully before deciding to use these drugs.

Ultimately, when it comes to eliminating dis-ease symptoms, we all have to make big decisions. Should we quickly reach for a pharmaceutical drug? Or, is there a more natural (safer) way to enhance immune function and regain our health?

Sources for this article include:

CDN.Turner.com
Alzheimersanddementia.com
Harvard.edu
OrganicAllergyRelief.com
Fox13Now.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ANTHBOT N8 Wins Honors: A New Era in Lawn Care?

Updated Category News Views 33

Rising Above the Grass Well, here's a twist: ANTHBOT's latest robot mower, the N8, caught the eyes of TIME magazine and snagged a spot on their Best Inventions of 2026 list. A lawnmower? You bet. And not just any lawnmower—this one's doing a whole song and dance with its 4-in-1 approach that'll make any garden-owning homeowner's life simpler. Kudos to them for shaking...

Continue Reading
Human Judgment Crucial Amid AI Growth in Courts

Updated Category News Views 54

AI in the Justice System: Balancing Potential and Pitfalls You know, when it comes to upholding justice, there's a line between what machines can handle and what only a human can bring to the gavel. Chief Justice Sundaresh Menon of Singapore threw the spotlight on this at an event in Brisbane, hammering home the need for good ole human intuition in the courtroom even as...

Continue Reading
Armenia's Mining Sector Eyes Future Opportunities

Updated Category News Views 57

The Changing Landscape of Armenia's Mining Sector Crack open a map of Armenia, and you're staring at a mineral-rich ground ripe for opportunity. That's the lay of the land that the third annual Mining Armenia Forum 2026 zoomed in on, with more than 30 presentations tackling the future of responsible mining, investment, and technology. Taking over the mountain air in...

Continue Reading
ACTEC Welcomes 55 New Fellows: A Closer Look

Updated Category News Views 115

Coffee's brewing hot, and so are the stakes at ACTEC, where 55 new Fellows just got the nod. The American College of Trust and Estate Counsel isn't your average club. They've been at this game since 1949, bringing together the finest minds in trusts and estates. But what does this newest batch bring to the table, and why should investors take a moment to notice? A Diverse...

Continue Reading
ATI's Financial Runway: $1.42B Sales and Rising

Updated Category News Views 46

ATI's Stellar Third Quarter: Beyond Expectations Today, ATI Inc. dropped a third-quarter performance that's got Wall Street abuzz—in a good way. The numbers speak volumes: ATI's sales soared by 26% to reach a cool $1.42 billion, smashing last year's results to bits. If you were banking on NYSE:ATI to keep your portfolio afloat, well, let's just say you're sitting...

Continue Reading
Stora Enso Charts Ambitious Path with Demerger Plan

Updated Category News Views 24

Setting the Stage for Strategic Shifts Alright, folks, Stora Enso, that old behemoth of the paper and forest game, is at it again, shaking things up in a way only veterans of the industry can. They're no strangers to the cutthroat nature of this business, and it looks like they're ready to roll the dice for a new chapter. Amid an inflation-induced rollercoaster where...

Continue Reading
ZKONG, Hagebau Push ESLs in European Retail Revamp

Updated Category News Views 58

ESLs: The Next Step in Retail Revamp Here’s the scoop: ZKONG and hagebau are making waves in the retail scene over in Germany. They’re bringing in Electronic Shelf Labels (ESLs) to kick traditional price tags to the curb. What started as a shake-up in supermarkets now rolls into the world of home improvement retail—headline by hagebaumarkt in Selb after nearly half...

Continue Reading
Broadway.com Instagram Reaches Million Followers Milestone

Updated Category News Views 54

Broadway.com's Instagram Ascends to Iconic Status There it is, folks—Broadway.com's Instagram just threw down the gauntlet with a clean, million-follower milestone. That's right, a hefty chunk of people now have a front-row seat to Broadway's electric world, straight from their phones. If you're a Broadway buff or just a casual admirer of glitz and glam, these numbers...

Continue Reading
RPC Reports Q3 Loss Amid Revenue Growth Quirks

Updated Category News Views 111

RPC Rides Out a Rough Quarter with Strategic Moves Ah, the oilfield services game—never a dull moment, right? RPC, Inc. just dropped their Q3 2026 results, and there’s a mixed bag to digest here. On the one hand, they saw a modest 1% uptick in revenue, hitting $467.7 million. But on the flip side, they're grappling with a hefty net loss of $41.9 million thanks to a...

Continue Reading
Dermatology Access Expands in Kansas With Expert Return

Updated Category News Views 35

Jenna King's Return Elevates Local Care Who says you can't go home again? Jenna King, a familiar face in Southeast Kansas, is back to serve her community by upping the ante in dermatology care at U.S. Dermatology Partners in Pittsburg. After gaining experience in Oklahoma, she's here to extend both medical and cosmetic treatments to her neighbors. Why Her Return Is a Game...

Continue Reading

Top 5 Most Recently Viewed Articles

United Community Banks Declares Quarterly Dividend for Investors

Updated Category News Views 81

United Community Banks, Inc. Declares Quarterly Cash Dividend United Community Banks, Inc. (NYSE: UCB) has made an exciting announcement regarding its preferred stock dividends, affirming its dedication to rewarding shareholders. The Board of Directors has approved a quarterly cash dividend set at $429.6875 per share. This translates to $0.4296875 for each depositary...

Continue Reading
Tempest’s Amezalpat Therapy Receives Crucial Approval in China

Updated Category News Views 214

Tempest Therapeutics Advances Amezalpat in Pivotal Trial Tempest Therapeutics, Inc. (Nasdaq: TPST) is thrilled to announce a major step forward in the fight against hepatocellular carcinoma (HCC), having received approval from China’s National Medical Products Administration (NMPA) to initiate a pivotal trial. This trial aims to evaluate the efficacy of amezalpat...

Continue Reading
Exploring the Growth of Hydrophilic Coating Market Trends

Updated Category News Views 150

Overview of the Hydrophilic Coating Market Growth The hydrophilic coating market is on a remarkable trajectory, with projections indicating a growth from USD 16.59 billion in 2023 to USD 27.23 billion by 2032, translating to a compound annual growth rate (CAGR) of 5.66% during this period. This surge is largely driven by advancements in biomedical technology and an...

Continue Reading
Counterweight Market Growth: Key Insights for Investors

Updated Category News Views 142

Counterweight Market Overview and Projected Growth The counterweight market is witnessing accelerated expansion, expected to reach approximately USD 6.1 billion by the year 2031. With a robust growth rate of around 4.9% during the forecast period, this sector is driven by the increasing demand across a wide range of applications. From elevators and forklifts to cranes and...

Continue Reading
VerticalScope Set to Reveal 2024 Financial Outcomes Soon

Updated Category News Views 193

VerticalScope Prepares for 2024 Financial Results Announcement VerticalScope Holdings Inc. (TSX: FORA; OTCQX: VFORF) is gearing up to unveil its fourth quarter and full year financial results for 2024. This announcement is eagerly awaited by investors and community members alike, as it reflects the company's performance and growth in the digital enthusiast platform space....

Continue Reading